TIDMDEST
Destiny Pharma PLC
06 July 2023
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Positive findings from recent Scientific Advisory Board
meeting
Confirms proposed Phase 3 development pathway and identifies new
life cycle management targets for XF-73 Nasal
Brighton, United Kingdom - 6 July 2023 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development and commercialisation of novel medicines to prevent
life threatening infections, recently held a meeting with its
Scientific Advisory Board and a number of international experts
from the UK and US focused on the XF-73 Nasal development
programme.
The panel of surgeons and infectious disease experts concluded
that:
-- The proposed XF-73 Nasal programme, consisting of two
placebo-controlled surgical phase 3 studies with a clinical
endpoint, designed around FDA input, reflects the utility of XF-73
Nasal in all surgeries.
-- The rapid antimicrobial action of XF-73 Nasal gives greater
flexibility in the scheduling of surgeries than existing offerings
and provides direct value to patients and institutions.
-- Antimicrobial resistance remains of global importance, with
S. aureus and resistant strains such as MRSA and MupRSA of great
concern clinically. XF-73 Nasal, through its unique and rapid
mechanism of action, can play an important role in antibiotic
stewardship by reducing the need for post-op systemic antibiotics.
Additionally, XF-73 Nasal could prevent horizontal transmission of
S. aureus, thus further contributing to good antibiotic
stewardship.
-- New potential life cycle management indications are available
for Destiny to explore, particularly in children (and their
families), where there are concerns over the use of mupirocin and
antiseptic approaches and a high unmet medical need remains.
Dr. Raghbir Khakha, Consultant Orthopaedic & Specialist Knee
Surgeon. Guy's and St Thomas', London, said: "XF-73 Nasal's fast
action and the consequent proposed dosing are a great advantage to
patients and institutions, as it can be used in emergency cases and
avoids rescheduling appointments when Staphylococcus aureusis
discovered. In other words, XF-73 Nasal can help avoid empty
operating theatres and maximize efficiencies in hospitals across
the country."
Prof. Richard Proctor, Professor Emeritus of the Department of
Medical Microbiology/Immunology and Professor Emeritus of the
Department of Medicine, University of Wisconsin School of Medicine
and Public Health Madison, Wisconsin, said: "Destiny's Phase 3
programme is designed to provide the FDA with the evidence they
need on clinical efficacy in infection prevention across a wide
range of surgeries. In addition, it is important that Destiny
continues to collect the microbiological data, as it has done in
the phase 2 cardiac surgery study, to confirm efficacy against all
circulating strains of Staphylococcus aureus, including MRSA and
mupirocin resistant strains, and to confirm the lack of development
of resistance on treatment. Completion of these studies should
demonstrate that XF-73 Nasal has an important role to play as part
of antibiotic stewardship in hospitals and the community."
Dr. Debra Barker, Interim Chief Executive Officer of Destiny
Pharma, said: "This thought-provoking meeting has confirmed Destiny
Pharma is on the right path and that XF-73 Nasal provides a
much-needed addition to the armory against AMR and surgical site
infections."
Destiny Pharma has recently completed detailed interactions with
the regulators and identified options for the final Phase 3
clinical development stage to obtain approval for the XF-73 Nasal
gel product in the US and Europe. The Company is actively seeking
partners for the XF-73 Nasal programme.
The following international experts participated in the
meeting:
-- Prof. E. Patchen Dellinger, Associate Medical Director,
University of Washington Medical Center
-- Dr. Raghbir Khakha, Consultant Orthopaedic & Specialist
Knee Surgeon. Guy's and St Thomas', London
-- Prof. Julie Mangino, Professor Emeritus, Department of
Internal Medicine, Division of Infectious Diseases, The Ohio State
University
-- Dr. Alexander Mericli, Associate Professor of Plastic
Surgery. The University of Texas, MD Anderson Cancer Center
-- Prof. Leonard Mermel, Professor of Medicine, Warren Alpert
Medical School of Brown University, Adjunct Clinical Professor,
University of Rhode Island College of Pharmacy and Medical Director
of the Department of Epidemiology & Infection Control for the
Lifespan Hospital System
-- Prof. Richard Proctor, Professor Emeritus of the Department
of Medical Microbiology/Immunology and Professor Emeritus of the
Department of Medicine, University of Wisconsin School of Medicine
and Public Health Madison, Wisconsin
-- Prof. David Roblin, Chair of Scientific Translation at The
Francis Crick Institute and Chair of Destiny Pharma SAB
-- Prof. Mark Wilcox, Consultant microbiologist, Head of
Research and Development in Microbiology, Leeds Teaching Hospitals
(LTHT)
Destiny Pharma representatives included Dr. Debra Barker (CEO),
Dr. Yuri Martina (CMO) and Dr. William Love (CSO).
- END -
For further information, please contact:
Destiny Pharma plc
Debra Barker, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
+44 (0) 7931 5000 66
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2 clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV(TM) ,
a novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
drug research projects.
For further information on the company, please visit
www.destinypharma.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAKXSEAEDEFA
(END) Dow Jones Newswires
July 06, 2023 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
過去 株価チャート
から 4 2024 まで 5 2024
Destiny Pharma (LSE:DEST)
過去 株価チャート
から 5 2023 まで 5 2024